Edesa Biotech (EDSA) has released an update.
Edesa Biotech, a biopharmaceutical company, is set to engage in a Fireside Chat and host meetings at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 28, 2024. The company specializes in developing treatments for immune-related conditions and is currently advancing its lead drug candidate, EB05, in a Phase 3 study for ARDS, while also preparing to study its effects on pulmonary fibrosis and other autoimmune diseases. Edesa’s innovative approach to tackling inflammatory disorders positions it as a company to watch for those following biotech advancements.
For further insights into EDSA stock, check out TipRanks’ Stock Analysis page.
